Cancer Family
Hematopoietic and Lymphoid Cell Neoplasm
CI-CAN-00000023Explore in graph →
HematologicNon-malignant4,231 active trials98 approved drugs1,009 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000023Explore in graph →
Clinical trials
18,680 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05296304 | A Study of Bexarotene Combined With Radiotherapy in People With Mycosis Fungoides | recruiting | Phase 1 | 20 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT05892718 | A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors | recruiting | Phase 1 | 80 | FBD Biologics LimitedINDUSTRY | 3 | Feb 4, 2026 | clinicaltrials |
| NCT07383233 | CD19/BAFF-R in Vivo CAR-T Cell Therapy Targeting Relapsed/Refractory B Cell Acute Leukemia/Malignant Lymphoma | not yet recruiting | Phase 1 | 18 | Qi dengOTHER | 0 | Feb 3, 2026 | clinicaltrials |
| NCT04323956 | Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma | active not recruiting | Phase 1 | 50 | Mayo ClinicOTHER | 1 | Feb 2, 2026 | clinicaltrials |
| NCT07114939 | FTT PET/CT in Pancreatic Neuroendocrine Tumors | recruiting | Phase 1 | 12 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Feb 2, 2026 | clinicaltrials |
| NCT04390737 | Evaluate the Safety and Clinical Activity of HH2853 | recruiting | Phase 1 / Phase 2 | 254 | Haihe Biopharma Co., Ltd.INDUSTRY | 2 | Jan 30, 2026 | clinicaltrials |
| NCT04669171 | A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma(SIDNEY) | recruiting | Phase 1 / Phase 2 | 80 | EnteromeINDUSTRY | 4 | Jan 30, 2026 | clinicaltrials |
| NCT06357676 | Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial | recruiting | Phase 1 / Phase 2 | 27 | OHSU Knight Cancer InstituteOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT06756451 | This Study is a FIH Study Which is Required to Understand the PK Characteristics, MTD, RP2D and Safety Profile. | recruiting | Phase 1 | 71 | Nanjing RegeneCore Biotech Co., Ltd.INDUSTRY | 1 | Jan 30, 2026 | clinicaltrials |
| NCT06829771 | Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma | recruiting | Phase 1 / Phase 2 | 90 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jan 30, 2026 | clinicaltrials |
| NCT07114367 | NB02(POSELTINIB) Monotherapy in R/R Non-Hodgkin's Lymphoma(POTENTIAL-M) | recruiting | Phase 1 | 9 | NOBO MedicineINDUSTRY | 1 | Jan 30, 2026 | clinicaltrials |
| NCT05016947 | Venetoclax Plus Inotuzumab for B-ALL | active not recruiting | Phase 1 | 23 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT05371132 | Study to Evaluate CD8 PET Imaging as a Marker of Immune Response to Stereotactic Body Radiation Therapy (ELIXR) | recruiting | Phase 1 | 10 | City of Hope Medical CenterOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT05455294 | Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms | active not recruiting | Phase 1 | 16 | Jacqueline Garcia, MDOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT06484985 | Study of AXT-1003 in Subjects With Advanced Malignant Tumors. | recruiting | Phase 1 | 78 | Axter Therapeutics (Beijing) Co., LtdINDUSTRY | 1 | Jan 28, 2026 | clinicaltrials |
| NCT07321626 | Romiplostim N01 for Platelet Recovery After Haploidentical HSCT | recruiting | Phase 1 | 130 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT07368270 | Safety and Efficacy Study of Anti-PD1 Armored CD19 CAR-T Cells in Adult Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma | recruiting | Phase 1 | 30 | Jiangsu Topcel-KH Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 28, 2026 | clinicaltrials |
| NCT03842696 | Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation | active not recruiting | Phase 1 / Phase 2 | 43 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jan 27, 2026 | clinicaltrials |
| NCT07369895 | Clinical Study of O&D-001 Injection in the Treatment of Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 | 18 | O&D BioTech Group CO., LimitedINDUSTRY | 1 | Jan 27, 2026 | clinicaltrials |
| NCT07370064 | Clinical Study of Anti-CLL1-CD33-NKG2D Bicephali CAR-T for Relapsed/Refractory Acute Myeloid Leukemia(AML CAR-T) | not yet recruiting | Phase 1 / Phase 2 | 20 | Xuzhou Medical UniversityOTHER | 1 | Jan 27, 2026 | clinicaltrials |
| NCT07367685 | Clinical Study of Universal CD19 CAR-γδT Cell Injection in the Treatment of Adult Relapsed/Refractory B-cell Lymphoma | not yet recruiting | Phase 1 | 6 | The Second Affiliated Hospital of Fujian Medical UniversityOTHER | 1 | Jan 26, 2026 | clinicaltrials |
| NCT05071209 | Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 31 | National Cancer Institute (NCI)NIH | 2 | Jan 23, 2026 | clinicaltrials |
| NCT06326463 | CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies | recruiting | Phase 1 | 18 | St. Jude Children's Research HospitalOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT07362095 | Luspatercept for the Treatment of Anemia Following Allogeneic Hematopoietic Stem Cell Transplantation(Allo-HSCT)(Allo-HSCT) | recruiting | Phase 1 / Phase 2 | 46 | Zhujiang HospitalOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT07361029 | CD19 Chimeric Antigen Receptor (CAR) T Cells in Adults With Relapsed/Refractory CD19 Positive Acute Lymphoblastic Leukemia(CD19 CART CELL) | recruiting | Phase 1 | 24 | King Faisal Specialist Hospital & Research CenterOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT04855695 | Avo In R/R And Previously Untreated MCL | recruiting | Phase 1 / Phase 2 | 72 | Austin I KimOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT05001828 | Study of ADI-PEG 20, Venetoclax and Azacitidine in Acute Myeloid Leukemia | active not recruiting | Phase 1 | 38 | Polaris GroupINDUSTRY | 1 | Jan 21, 2026 | clinicaltrials |
| NCT04223765 | Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. | recruiting | Phase 1 | 20 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT04586426 | A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma(RedirecTT-1) | active not recruiting | Phase 1 / Phase 2 | 228 | Janssen Research & Development, LLCINDUSTRY | 7 | Jan 16, 2026 | clinicaltrials |
| NCT05143996 | CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) | recruiting | Phase 1 | 60 | Cullinan Therapeutics Inc.INDUSTRY | 1 | Jan 16, 2026 | clinicaltrials |
| NCT05222555 | Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients(MINDway) | active not recruiting | Phase 1 / Phase 2 | 53 | Incyte CorporationINDUSTRY | 9 | Jan 16, 2026 | clinicaltrials |
| NCT05737628 | First-in-human Dose Escalation and Expansion Study With the SIRPα-directed Monoclonal Antibody BYON4228 | active not recruiting | Phase 1 | 17 | Byondis B.V.INDUSTRY | 4 | Jan 16, 2026 | clinicaltrials |
| NCT06768476 | CART123 + Ruxolitinib in Relapsed/Refractory AML(AML) | active not recruiting | Phase 1 | 12 | University of PennsylvaniaOTHER | 1 | Jan 16, 2026 | clinicaltrials |
| NCT07347171 | A Phase 1 Study of CG009301 for Injection in Adult Subjects With Recurrent or Refractory Haematological Malignancies | recruiting | Phase 1 | 45 | Cullgen (Shanghai),IncOTHER | 1 | Jan 16, 2026 | clinicaltrials |
| NCT05287568 | CC-486 and Venetoclax for Acute Myeloid Leukemia | recruiting | Phase 1 | 35 | University of Colorado, DenverOTHER | 1 | Jan 15, 2026 | clinicaltrials |
| NCT06429449 | Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia | recruiting | Phase 1 | 30 | University of Colorado, DenverOTHER | 1 | Jan 15, 2026 | clinicaltrials |
| NCT05942599 | Base Edited CAR T Cells Against AML: Deep Conditioning Ahead of Allogeneic Stem Cell Transplantation(CARAML) | active not recruiting | Phase 1 | 10 | Great Ormond Street Hospital for Children NHS Foundation TrustOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT07339527 | EZH2 Inhibitor Zeprumetostat in Combination Therapy for Patients With Relapsed or Refractory Mature T-cell and NK-cell Lymphomas | not yet recruiting | Phase 1 / Phase 2 | 60 | Sun Yat-sen UniversityOTHER | 0 | Jan 14, 2026 | clinicaltrials |
| NCT06755450 | Study Evaluating Safety Pharmacokinetics and Pharmacodynamics of AUR112 in Patients With Relapsed Advanced Lymphoma(ADITI-1) | recruiting | Phase 1 | 40 | Aurigene Discovery Technologies LimitedINDUSTRY | 1 | Jan 13, 2026 | clinicaltrials |
| NCT07333469 | A Clinical Study of HX111 in Patients With Advanced Solid Tumor and Lymphoma | not yet recruiting | Phase 1 / Phase 2 | 70 | Hanx Biopharmaceuticals (Wuhan) Co., Ltd.INDUSTRY | 0 | Jan 13, 2026 | clinicaltrials |
| NCT07334574 | Clinical Study of XP-006 mRNA Vaccine for R/R B-NHL(XP-006) | not yet recruiting | Phase 1 | 20 | Ruijin HospitalOTHER | 1 | Jan 13, 2026 | clinicaltrials |
| NCT03829254 | A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma | recruiting | Phase 1 / Phase 2 | 135 | NuCana plcOTHER | 1 | Jan 12, 2026 | clinicaltrials |
| NCT05317403 | Venetoclax to Augment Epigenetic Modification and Chemotherapy | recruiting | Phase 1 | 40 | Medical College of WisconsinOTHER | 1 | Jan 12, 2026 | clinicaltrials |
| NCT06163430 | A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL)(CARDINAL) | recruiting | Phase 1 / Phase 2 | 180 | Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 9 | Jan 12, 2026 | clinicaltrials |
| NCT07333430 | Study of Naive HBI0101 CAR-T Therapy in Relapsed/Refractory Multiple Myeloma | recruiting | Phase 1 | 60 | Hadassah Medical OrganizationOTHER | 1 | Jan 12, 2026 | clinicaltrials |
| NCT04686682 | A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors | recruiting | Phase 1 / Phase 2 | 152 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 9, 2026 | clinicaltrials |
| NCT04872478 | Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults With Relapsed/Refractory AML, ALL, or MPAL | recruiting | Phase 1 | 50 | Meryx, Inc.INDUSTRY | 1 | Jan 8, 2026 | clinicaltrials |
| NCT05211336 | Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System | active not recruiting | Phase 1 | 14 | National Cancer Institute (NCI)NIH | 1 | Jan 8, 2026 | clinicaltrials |
| NCT05342584 | Venetoclax Plus Intensive Chemotherapy in AML and Advanced MDS(Venetoclax AML) | recruiting | Phase 1 | 99 | Montefiore Medical CenterOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT05464329 | Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Patients With Relapsed/Refractory Aggressive B Cell Lymphoma | active not recruiting | Phase 1 | 24 | Washington University School of MedicineOTHER | 1 | Jan 8, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Feb 4, 2026source: clinicaltrials